Clinical Trials
28 trials18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer
National Institutes of Health Clinical Center (CC)
Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial
National Cancer Institute (NCI)
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
National Institutes of Health Clinical Center (CC)
Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors
National Cancer Institute (NCI)
Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer
National Cancer Institute (NCI)
18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer
National Institutes of Health Clinical Center (CC)
Positron Emission Tomography and Computed Tomography in Guiding Radiation Therapy for Stage III Non-small Cell Lung Cancer
National Cancer Institute (NCI)
18F-DCFPyL PET/CT in Hepatocellular Carcinoma
National Institutes of Health Clinical Center (CC)
F-18 16 Alpha-Fluoroestradiol-Labeled Positron Emission Tomography in Predicting Response to First-Line Hormone Therapy in Patients With Stage IV Breast Cancer
National Cancer Institute (NCI)
Saracatinib in Treating Patients With Previously Treated Metastatic Pancreatic Cancer
National Cancer Institute (NCI)
Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131
National Cancer Institute (NCI)
Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma
National Cancer Institute (NCI)
Triapine, Cisplatin, and Radiation Therapy in Treating Patients With Cervical Cancer or Vaginal Cancer
National Cancer Institute (NCI)
18F-Fluoromisonidazole and Fludeoxyglucose F 18 PET/CT Patients With Soft Tissue Sarcoma
National Cancer Institute (NCI)
Irinotecan and Cisplatin in Treating Patients Who Are Undergoing Surgery For Locally Advanced Cancer of the Stomach or Gastroesophageal Junction
National Cancer Institute (NCI)
Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas
National Institutes of Health Clinical Center (CC)
A Comparison of FLT to FDG PET/CT in the Early Assessment of Chemotherapy Response in Stage IB-IIIA Resectable NSCLC
National Cancer Institute (NCI)
Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy
National Cancer Institute (NCI)
Radiofrequency Ablation in Treating Patients With Unresectable Primary or Metastatic Liver Cancer
National Institutes of Health Clinical Center (CC)
FDG and FMISO PET Hypoxia Evaluation in Cervical Cancer
National Cancer Institute (NCI)
Sirolimus to Treat Cowden Syndrome and Other PTEN Hamartomatous Tumor Syndromes
National Institutes of Health Clinical Center (CC)
Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer
National Cancer Institute (NCI)
Pazopanib Hydrochloride in Treating Patients With Metastatic Urethral Cancer or Bladder Cancer That Has Relapsed or Not Responded to Treatment
National Cancer Institute (NCI)
Cisplatin, Gemcitabine Hydrochloride, and Sorafenib Tosylate in Treating Patients With Transitional Cell Cancer of the Bladder
National Cancer Institute (NCI)
17AAG to Treat Kidney Tumors in Von Hippel-Lindau Disease
National Institutes of Health Clinical Center (CC)
Positron Emission Tomography and CT Scan in Predicting Response in Patients With Metastatic Melanoma or Kidney Cancer Who Are Undergoing Cellular Adoptive Immunotherapy on a Surgery Branch Clinical Trial
National Institutes of Health Clinical Center (CC)
Fludeoxyglucose F18 Positron Emission Tomography Imaging In Assessing Patients Before and After Treatment for Locally Advanced Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase II Study of the Role of Anti-CEA Antibody Immunoscintigraphy & Positron Emission Tomography in the Localization of Recurrent Colorectal Carcinoma in Patients With Rising Serum CEA Levels in the Absence of Imageable Disease by Conventional Modalities
National Institutes of Health Clinical Center (CC)